License and Sublicense Agreement (May 9th, 2013)
This License and Sublicense Agreement (Agreement) is entered into by and between the Parties as of the Effective Date (as defined herein).
Coronado Biosciences, Inc. Employment Agreement (September 26th, 2011)
This EMPLOYMENT AGREEMENT (this Agreement) is made and entered into effective as of September 26, 2011 (the Effective Date) by and between CORONADO BIOSCIENCES, INC. (the Company) and Noah D. Beerman (the Executive). The Company and Executive are hereinafter collectively referred to as the Parties, and individually referred to as a Party.
March 30, 2011 Noah D. Beerman 10 Sawmill Road Acton, MA 01720 Dear Noah: (April 5th, 2011)
As we have discussed, your employment as President and Chief Executive Officer of RXi Pharmaceuticals Corporation (the Company) will terminate, effective as of the date of the public announcement of the merger between the Company and Apthera, Inc. (such date, the Separation Date, and this letter agreement, the Agreement). Reference is made to the Employment Agreement between you and the Company dated as of November 5, 2009 (the Employment Agreement). All capitalized terms used in this Agreement will have the meaning ascribed to them in the Employment Agreement unless otherwise expressly provided herein. The purpose of this letter is to confirm the agreement between you and the Company (each, a Party) concerning your separation from employment and severance benefits, as follows:
Employment Agreement (March 31st, 2010)
The Employment Agreement (the Agreement) is made and entered into as of November 5, 2009 (the Effective Date) by and between RXi Pharmaceuticals Corporation, a Delaware corporation (RXi, the Company, or Employer), and Noah D. Beerman, an individual and resident of the Commonwealth of Massachusetts (Employee).
CONFIDENTIAL Noah D. Beerman Chief Executive Officer RXi Pharmaceuticals Corporation 60 Prescott Street Worchester, Massachusetts 01605 Dear Mr. Beerman: (March 23rd, 2010)
This letter (the Agreement) constitutes the agreement between Rodman & Renshaw, LLC (Rodman or the Placement Agent) and RXi Pharmaceuticals Corporation (the Company), that Rodman shall serve as the exclusive placement agent for the Company, on a reasonable best efforts basis, in connection with the proposed placement (the Placement) of registered securities (the Securities) of the Company, including, but not limited to, shares (the Shares) of the Companys common stock, par value $0.0001 per share (the Common Stock). The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a Purchaser and collectively, the Purchasers) and nothing herein constitutes that Rodman would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and the documents executed and delivered by the Company and the Purchasers in connection with the Pla
Stock Redemption Agreement (March 23rd, 2010)
This Stock Redemption Agreement (Agreement) is entered into as of March 22, 2010 between RXi Pharmaceuticals Corporation, a corporation incorporated under the laws of Delaware (Corporation) and CytRx Corporation, a corporation incorporated under the laws of Delaware (Stockholder).
Indevus Pharmaceuticals Inc. – Retention Agreement (April 15th, 2008)
AGREEMENT by and between Indevus Pharmaceuticals, Inc., a Delaware corporation (the Company) and Noah D. Beerman (the Executive), effective as of April 11, 2008 (the Effective Date).
Indevus Pharmaceuticals Inc. – Amended and Restated Employment Agreement (November 30th, 2007)
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this Agreement), dated as of , 2007, between Indevus Pharmaceuticals, Inc., a Delaware Corporation having a place of business at 33 Hayden Avenue, Lexington, Massachusetts 02421 (the Corporation) and Noah D. Beerman, an individual residing at (the Executive).
Indevus Pharmaceuticals Inc. – Employment Agreement (April 6th, 2006)
Agreement dated March 31, 2006 effective as of March 31, 2006 (the Effective Date), by and between Indevus Pharmaceuticals, Inc., a Delaware corporation having a place of business at 33 Hayden Avenue, Lexington, Massachusetts 02421 (the Corporation), and Noah D. Beerman, an individual residing at 10 Sawmill Road, Acton, Massachusetts 01720 (the Officer).